Hoechst Pakistan Limited (PSX:HPL)

Market Cap	41.81B
Revenue (ttm)	30.81B
Net Income (ttm)	2.86B
Shares Out	9.64M
EPS (ttm)	296.83
PE Ratio	14.60
Forward PE	n/a
Dividend	160.00 (3.79%)
Ex-Dividend Date	Aug 22, 2025

Volume	13
Average Volume	163
Open	4,278.00
Previous Close	4,218.50
Day's Range	4,218.51 - 4,359.50
52-Week Range	2,506.00 - 4,537.00
Beta	0.27
RSI	63.13
Earnings Date	Feb 20, 2026

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 837
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HPL

Financial Performance

In 2024, Hoechst Pakistan's revenue was 26.75 billion, an increase of 25.17% compared to the previous year's 21.37 billion. Earnings were 1.86 billion, an increase of 414.72%.